Compare RGEN & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | GTLB |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | 2000 | N/A |
| Industry | Medical/Dental Instruments | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 5.5B |
| IPO Year | 1995 | 2021 |
| Metric | RGEN | GTLB |
|---|---|---|
| Price | $191.56 | $48.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 27 |
| Target Price | ★ $167.67 | $37.17 |
| AVG Volume (30 Days) | 829.9K | ★ 5.1M |
| Earning Date | 05-05-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $141,236,000.00 | ★ $955,224,000.00 |
| Revenue This Year | $14.30 | $18.72 |
| Revenue Next Year | $14.52 | $16.05 |
| P/E Ratio | $768.88 | ★ N/A |
| Revenue Growth | ★ 35.10 | 25.81 |
| 52 Week Low | $100.99 | $18.73 |
| 52 Week High | $188.95 | $55.55 |
| Indicator | RGEN | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 59.48 |
| Support Level | $158.15 | $46.01 |
| Resistance Level | $188.73 | $55.55 |
| Average True Range (ATR) | 5.50 | 1.77 |
| MACD | 0.85 | -0.36 |
| Stochastic Oscillator | 81.32 | 57.83 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.